Western Bloting: 1/500 - 1/2000. Immunohistochemistry: 1/200 - 1/1000. ELISA: Propose dilution 1/10000. Not yet tested in other applications. Determining optimal working dilutions by titration test.
限制
仅限研究用
状态
Liquid
储存液
Sodium azide
注意事项
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
储存条件
4 °C
Chrencik, Brooun, Recht, Kraus, Koolpe, Kolatkar, Bruce, Martiny-Baron, Widmer, Pasquale, Kuhn: "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity." in: Structure (London, England : 1993), Vol. 14, Issue 2, pp. 321-30, (2006) (PubMed).
Wu, Suo, Risberg, Karlsson, Villman, Nesland: "Expression of Ephb2 and Ephb4 in breast carcinoma." in: Pathology oncology research : POR, Vol. 10, Issue 1, pp. 26-33, (2004) (PubMed).
EPH receptor B4 (EphB4), with 987-amino acid protein (about 108kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. The Eph receptor tyrosine kinases and their ligands, the ephrins, regulate numerous biological processes in developing and adult tissues and have been implicated in cancer progression and in pathological forms of angiogenesis. EphB4 acts as a negative regulator of blood vessel branching and vascular network formation, switching the vascularization program from sprouting angiogenesis to circumferential vessel growth. EphB4 and its ligand ephrinB2 express in several kinds of tumor cells and correlate with tumorigenesis. EphB4 is thus a potential candidate as a predictor of disease outcome in several kinds of tumor and as target for novel therapy. Synonyms: HTK, MYK1, TYRO11